natgillin/translations-raw huggingface dataset:
There was no difference between the atosiban and beta-mimetic groups with regard to this parameter. 
Skupini, ki sta prejemali atoziban in beta-mimetik, se v tem pogledu nista razlikovali.
Multiple pregnancy and medicinal products with tocolytic activity like calcium channel blockers and beta-mimetics are known to be associated with increased risk of pulmonary oedema. 
Znano je, da sta mnogoplodna nosečnost in uporaba zdravil s tokolitičnim delovanjem, kot so zaviralci kalcijevih kanalčkov in beta-mimetiki, povezani z večjim tveganjem za pljučni edem.
No clinically relevant interaction was found between atosiban and bethamethasone or labetalol. 
Klinično pomembnih interakcij med atozibanom in betametazonom ali labetalolom niso opazili.
Following an infusion of 300 micrograms/min in healthy pregnant women at term, the fetal/maternal atosiban concentration ratio was 0.12. 
Po infuziji 300 mikrogramov/min zdravim nosečnicam ob roku je bilo razmerje med koncentracijo atozibana pri plodu in materi 0,12.
The safety and efficacy of atosiban in pregnant women aged less than 18 years have not been established. 
Varnost in učinkovitost atozibana pri nosečnicah, starih manj kot 18 let, nista bili dokazani.
The ratios of the main metabolite M1 (des-(Orn8, Gly-NH2 9) -29)-[Mpa1, D-Tyr(Et)2, Thr4]-oxytocin) to atosiban concentrations in plasma were 1.4 and 2.8 at the second hour and at the end of the infusion respectively. 
Razmerje med koncentracijo glavnega presnovka M1 (des-(Orn8, Gly-NH2 9) -29)-[Mpa1, D-Tyr(Et)2, Thr4]-oksitocin) in atozibana v plazmi je bilo po dveh urah 1,4 in na koncu infundiranja 2,8.
Clear, colourless solution without particles. 
Bistra, brezbarvna raztopina brez delcev.
Of the 361 women who received atosiban treatment in the phase III studies, 73 received at least one re-treatment, 8 received at least 2 re-treatments and 2 received 3 re-treatments (see section 4.4). 
Od 361 žensk, zdravljenih z atozibanom v študijah III. faze, je bilo zdravljenje ponovljeno vsaj enkrat pri 73 ženskah, vsaj dvakrat pri 8 ženskah, vsaj trikrat pa pri 2 ženskah (glejte poglavje 4.4).
There is only limited clinical experience in the use of atosiban in multiple pregnancies or the gestational age group between 24 and 27 weeks, because of the small number of patients treated. 
Klinične izkušnje z uporabo atozibana pri mnogoplodnih nosečnostih ali v gestacijski starosti od 24. do 27. tedna so zaradi majhnega števila zdravljenih bolnic omejene.
Do not use Atosiban SUN - If you are allergic to atosiban or any of the other ingredients of this medicine (listed in section 6). 
- Če ste alergični na atoziban ali katero koli sestavino tega zdravila (navedeno v poglavju 6).
Up to 270 mg intravenous infusion 
do 270 mg
Fetal and maternal outcome did apparently not differ between the atosiban and the β-agonist group, but the clinical trials were not powered enough to rule out a possible difference. 
Izid za plod in mater se v skupini z atozibanom po vsem sodeč ni razlikoval od izida v skupini z β agonistom, toda moč kliničnih preskušanj ni bila tolikšna, da bi izključila možno razliko.
Diluted solution for intravenous administration should be used within 24 hours after preparation. 
Razredčeno raztopino za intravensko aplikacijo je treba uporabiti v 24 urah po pripravi.
In rats and guinea pigs, atosiban was shown to bind to oxytocin receptors, to decrease the frequency of contractions and the tone of the uterine musculature, resulting in a suppression of uterine contractions. 
Pri podganah in budrah je dokazano, da se atoziban veže na receptorje za oksitocin, zmanjša pogostnost kontrakcij in tonus materničnega mišičja in tako zavre kontrakcije maternice.
Other medicines and Atosiban SUN 
Druga zdravila in zdravilo Atoziban SUN
In women in pre-term labour receiving atosiban by infusion (300 micrograms/min for 6 to 12 hours), steady state plasma concentrations were reached within one hour following the start of the infusion (mean 442 ± 73 ng/ml, range 298 to 533 ng/ml). 
Pri ženskah s prezgodnjim porodom, ki so dobile infuzijo atozibana (300 mikrogramov/min od 6 do12 ur), so bile plazemske koncentracije v stanju dinamičnega ravnovesja dosežene v eni uri po začetku infuzije (povprečno 442 ± 73 ng/ml, razpon od 298 do 533 ng/ml).
The total dose given during a full course of atosiban therapy should preferably not exceed 330.75 mg of atosiban. 
Skupni odmerek atozibana med celotnim ciklusom zdravljenja z atozibanom naj ne bi presegel 330,75 mg.
In patients with impaired hepatic function, atosiban should be used with caution. 
Pri bolnicah z okvaro delovanja jeter je treba atoziban uporabljati previdno.
Atosiban SUN is used in pregnant adult women, from week 24 to week 33 of the pregnancy. 
Zdravilo Atoziban SUN se uporablja pri odraslih nosečnicah od 24. do 33. tedna nosečnosti.
After dilution, the concentration of atosiban is 0.75 mg/ml. 
Po razredčenju je koncentracija atozibana 0,75 mg/ml.
In animals atosiban did not exhibit cardiovascular effects. 
Pri živalih atoziban ni imel kardiovaskularnih učinkov.
There are no known side effects on the unborn or newborn baby. 
Pri plodu ali novorojenčku ni znanih neželenih učinkov.
As an antagonist of oxytocin, atosiban may theoretically facilitate uterine relaxation and postpartum bleeding therefore blood loss after delivery should be monitored. 
Atoziban bi kot antagonist oksitocina teoretično lahko povzročil atonijo maternice in poporodno krvavitev, zato je po porodu treba nadzirati izgubo krvi.
If any of the above apply to you (or you are not sure), talk to your doctor, midwife or pharmacist before you are given Atosiban SUN. 
Če se karkoli od navedenega nanaša na vas (ali ste negotovi), se posvetujte s svojim zdravnikom, z babico ali s farmacevtom preden prejmete zdravilo Atoziban SUN.
What Atosiban SUN is and what it is used for What you need to know before you are given Atosiban SUN How Atosiban SUN will be given Possible side effects 
Kaj je zdravilo Atoziban SUN in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli zdravilo Atoziban SUN Kako vam bo zdravilo Atoziban SUN dano
PHARMACEUTICAL FORM Concentrate for solution for infusion (sterile concentrate). 
FARMACEVTSKA OBLIKA Koncentrat za raztopino za infundiranje (sterilni koncentrat)
- If you have bleeding from your vagina and your doctor wants your unborn baby to be delivered straight away. 
- Če krvavite iz nožnice in zdravnik meni, da je treba porod opraviti takoj.
- If your placenta is detaching from the wall of your womb. 
- Če se je posteljica odluščila od stene maternice.
Cluj-Napoca, Judeţul Cluj România tel. +40 (264) 501 500 
România tel. +40 (264) 501 500
Before using Atosiban SUN, the solution should be examined to ensure it is clear and free from particles. 
Pred uporabo zdravila Atoziban SUN morate raztopino pregledati in se prepričati, da je bistra in ne vsebuje trdnih delcev.
The infant adverse reactions were in the range of normal variation and were comparable with both placebo and beta-mimetic group incidences. 
Neželeni učinki pri dojenčkih so bili v območju normalnih variacij in po pogostnosti primerljivi s tistimi v skupini, ki je prejemala placebo in v skupini, ki je prejemala beta-mimetik.
In the case of persistence of uterine contractions during treatment with atosiban, alternative therapy should be considered. 
Če se kontrakcije maternice med zdravljenjem z atozibanom nadaljujejo, je treba razmisliti o alternativni terapiji.
The diluted solution must be used within 24 hours. 
Razredčeno raztopino morate porabiti v 24 urah.
Mean (SD) birth weight was 2491 (813) grams in the atosiban group and 2461 (831) grams in the β-agonist group (p=0.58). 
Povprečna (SD) porodna masa je bila v skupini z atozibanom2.491 (813) gramov in v skupini z β-agonistom 2.461 (831) gramov (p = 0,58).
The proportion of atosiban eliminated in faeces is not known. 
Delež v blatu izločenega atozibana ni znan.
If during pregnancy the woman is already breast-feeding an earlier child, then breast-feeding should be discontinued during treatment with atosiban, since the release of oxytocin during breast-feeding may augment uterine contractility, and may counteract the effect of tocolytic therapy. 
Če nosečnica še doji prejšnjega otroka, mora med zdravljenjem z atozibanom prenehati dojiti, saj lahko izločanje oksitocina med dojenjem okrepi maternične kontrakcije in nasprotuje učinkom tokolitičnega zdravljenja.
In healthy non-pregnant subjects receiving atosiban infusions (10 to 300 micrograms/min over 12 hours), the steady state plasma concentrations increased proportionally to the dose. 
Pri zdravih, nenosečih preiskovankah, ki so dobile infuzijo atozibana (od 10 do 300 mikrogramov/min v 12 urah), so se plazemske koncentracije v stanju dinamičnega ravnovesja povečevale sorazmerno z odmerkom.
The side effects seen in the mother are generally mild. 
Pri materi so neželeni učinki običajno blagi.
Intravenous therapy using the initial bolus injection of atosiban 6.75 mg/0.9 ml, solution for injection (see Summary of Product Characteristics of this medicinal product) should be started as soon as possible after diagnosis of pre-term labour. 
Intravensko zdravljenje z začetno bolusno injekcijo zdravila atozibana 6,75 mg/0,9 ml raztopina za injiciranje (glejte povzetek glavnih značilnosti zdravila za to zdravilo) je treba začeti čim prej po diagnozi prezgodnjega poroda.
It is unlikely that atosiban is involved in cytochrome P450 mediated drug-drug interactions as in vitro investigations have shown that atosiban is not a substrate for the cytochrome P450 system, and does not inhibit the medicinal product metabolising cytochrome P450 enzymes. 
P450 je majhna, saj in vitro raziskave kažejo, da atoziban ni substrat za encime citokrom P450 in ne zavira encimov citokrom P450, ki presnavljajo zdravila.
Mean (SD) gestational age at delivery was the same in the two groups: 35.6 (3.9) and 35.3 (4.2) weeks for the atosiban and β-agonist groups, respectively (p=0.37). 
Povprečna (SD) gestacijska starost ob porodu je bila v obeh skupinah enaka: 35,6 (3,9) tedna v skupini z atozibanom in 35,3 (4,2) tedna v skupini z β-agonistom (p = 0,37).
Treatment with Atosiban SUN can be repeated up to three more times. 
Zdravljenje z zdravilom Atoziban SUN se lahko ponovi še največ trikrat.
- If your unborn baby (foetus) has an abnormal heart rate. 
- Če ima plod (fetus) nepravilen srčni utrip.
In patients with impaired hepatic function, atosiban should be used with caution (see sections 4.2 and 5.2). 
Pri bolnicah z okvaro delovanja jeter je treba atoziban uporabljati previdno (glejte poglavji 4.2 in 5.2).
Atosiban is indicated to delay imminent pre-term birth in pregnant adult women with: - regular uterine contractions of at least 30 seconds duration at a rate of ≥ 4 per 30 minutes - a cervical dilation of 1 to 3 cm (0-3 for nulliparas) and effacement of ≥ 50% - a gestational age from 24 until 33 completed weeks - a normal foetal heart rate 
Atoziban je indiciran za odložitev iminentnega prezgodnjega poroda pri odraslih nosečnicah z: - rednimi kontrakcijami maternice, ki trajajo vsaj 30 sekund, s pogostnostjo ≥ 4 na 30 minut; - odprtjem materničnega vratu od 1 do 3 cm (od 0 do 3 cm pri ženskah, ki še niso rodile) in stanjšanjem za ≥ 50 %; - gestacijsko starostjo od 24 do 33 dopolnjenih tednov - normalno srčno frekvenco ploda
1 vial (6.75 mg/0.9 ml) 
1 viala (6,75 mg/0,9 ml)
- The other ingredients are mannitol, hydrochloric acid 1M and water for injections. 
- Pomožne snovi so manitol, klorovodikova kislina 1M in voda za injekcije.
Atosiban was neither oncogenic nor mutagenic in in vitro and in vivo tests. 
V raziskavah in vitro in in vivo atoziban ni deloval onkogeno ali mutageno.
The main metabolite M1 is approximately 10 times less potent than atosiban in inhibiting oxytocin-induced uterine contractions in vitro. 
Glavni presnovek M1 je pri in vitro zaviranju z oksitocinom povzročene kontrakcije maternice približno 10-krat manj učinkovit od atozibana.
Rare (may affect less than 1 in 1,000 people) - Your womb may be less able to contract after your baby has been born. 
Redki (neželeni učinki, ki se lahko pojavijo pri manj kot 1 od 1.000 bolnic) - Po porodu se lahko zmanjša sposobnost maternice za skrčitev.
The reconstituted medicinal product is a clear, colourless solution without particles. 
Zdravilo, pripravljeno za uporabo, je bistra, brezbarvna raztopina brez delcev.
One pack contains one vial containing 5 ml solution. 
Eno pakiranje vsebuje eno vialo z 5 ml raztopine.
Once the bolus has been injected, proceed with the infusion (See Summary of Product Characteristics of Atosiban SUN 37.5 mg/5 ml, concentrate for solution for infusion). 
Ko je bolus injiciran, je treba nadaljevati z infuzijo (glejte povzetek glavnih značilnosti zdravila Atoziban SUN 37,5 mg/5 ml koncentrat za raztopino za infundiranje).
In patients with impaired hepatic function, atosiban should be used with caution (see sections 4.2 and 4.4). 
Pri bolnicah z okvaro delovanja jeter je treba atoziban uporabljati previdno (glejte poglavji 4.2 in 4,4).
The data show that 59.6% (n=201) and 47.7% (n=163) of atosiban- and β-agonist-treated women (p=0.0004), respectively, were undelivered and did not require alternative tocolysis within 7 days of starting treatment. 
Podatki kažejo, da ni rodilo in v 7 dneh po začetku zdravljenja ni potrebovalo alternativnega tokolitičnega zdravljenja 59,6 % (n = 201) žensk, ki so dobivale atoziban, in 47,7 % (n = 163) žensk, ki so dobivale β-agonist (p = 0,0004).
The loading infusion is given by infusing 24 ml/hour (i.e. 18 mg/h) of the above prepared solution over the 3 hour period under adequate medical supervision in an obstetric unit. 
Polnilna infuzija se aplicira z infundiranjem tako pripravljene raztopine s hitrostjo 24 ml/uro (tj.18 mg/uro) v 3 urah pod ustreznim zdravniškim nadzorom na porodnem oddelku.
- If your waters have broken (premature rupture of your membranes) and you have completed 
- Če menite, da vam je odtekla voda (predčasni razpok plodovega mehurja).
LIST OF EXCIPIENTS Excipients: mannitol, hydrochloric acid 1M, water for injections. 
Pomožne snovi: manitol, klorovodikova kislina 1M, voda za injekcije.
Colourless tubular glass vial (type I) with bromobutyl flange grey rubber stopper and sealed with flip off violet colour aluminium seal. 
Viala iz brezbarvnega, prozornega cevkastega stekla (tip I) zaprta s sivim bromobutilnim gumijastim zamaškom in zatesnjena z aluminijasto zaporko »flip off« vijolične barve.
- If your contractions start again, treatment with Atosiban SUN can be repeated up to three more times. 
- Če se popadki začnejo znova, se lahko zdravljenje z zdravilom Atoziban SUN ponovi še največ trikrat.
It is unlikely that atosiban inhibits hepatic cytochrome P450 isoforms in humans (see section 4.5). 
Verjetnost, da bi atoziban pri človeku zaviral izoencime jetrnega citokroma P450, je majhna (glejte poglavje 4.5).
Embryo-fetal toxicity studies have not shown toxic effects of atosiban. 
Pri študijah toksičnosti na zarodek/plod niso odkrili škodljivih vplivov atozibana.
Severe pre-eclampsia is when you have very high blood pressure, 
Bolezenski znaki eklampsije so podobni kot pri hudi preeklampsiji,
The following information is intended for healthcare professionals only: (See also section 3) 
NAVODILA ZA ZDRAVSTVENO OSEBJE Naslednje informacije so namenjene samo zdravstvenemu osebju:
- If you have any further questions, ask your doctor, midwife or pharmacist. 
- Če imate dodatna vprašanja, se posvetujte z zdravnikom, z babico (pomočnico pri porodu) ali farmacevtom.
45 hours, or until your contractions have stopped. 
Ta infuzija bo trajala do 45 ur ali dokler kontrakcije maternice ne bodo minile.
In the CAP-001 studies the probability of remaining undelivered and not requiring alternative tocolytics within 7 days of treatment initiation was similar for atosiban and beta-mimetics treated women at gestational age of 24-28 weeks. 
Verjetnost, da ne pride do poroda in da v 7 dneh od začetka zdravljenja niso potrebni alternativni tokolitiki, je bila v študijah CAP-001 pri ženskah, zdravljenih v obdobju od 24. do 28. tedna gestacije,
Atosiban should only be used when pre-term labour has been diagnosed between 24 and 33 completed weeks of gestation. 
Atoziban se sme uporabiti le, če je postavljena diagnoza prezgodnjega poroda med 24. in33.
In case a re-treatment with atosiban is needed, it should also commence with a bolus injection of atosiban 6.75 mg/0.9 ml, solution for injection followed by infusion with atosiban 37.5 mg/5 ml, concentrate for solution for infusion. 
Če je potrebno ponovno zdravljenje z atozibanom, ga je treba zopet začeti z bolusno injekcijo atozibana 6,75 mg/0,9 ml raztopina za injiciranje, ki ji sledi infuzija atozibana 37,5 mg/5 ml koncentrat za raztopino za infundiranje.
- If you are pregnant with more than one baby. 
- Če pričakujete več kot enega otroka (mnogoplodna nosečnost).
SPECIAL STORAGE CONDITIONS 
9 POSEBNA NAVODILA ZA SHRANJEVANJE
Withdraw 0.9 ml of a 0.9 ml labelled vial of atosiban 6.75 mg/0.9 ml, solution for injection and administer slowly as an intravenous bolus dose over one minute, under adequate medical supervision in an obstetric unit. 
Izvlecite 0,9 ml iz 0,9-ml označene viale atozibana 6,75 mg/0,9 ml raztopina za injiciranje in aplicirajte počasi v intravenskem bolusu eno minuto pod ustreznim zdravniškim nadzorom na porodnem oddelku.
In total 48% of the patients treated with atosiban experienced adverse reactions during the clinical trials. 
Med kliničnimi preskušanji so se neželeni učinki pojavili pri 48 % vseh bolnic, ki so se zdravile z atozibanom.
Uncommon (may affect less than 1 in 100 people) - High temperature (fever). 
Občasni (neželeni učinki, ki se lahko pojavijo pri manj kot 1 od 100 bolnic) - Zvišana telesna temperatura (vročina).
For the newborn, the clinical trials did not reveal any specific adverse reactions of atosiban. 
Pri novorojenčkih klinična preskušanja niso pokazala nobenih specifičnih neželenih učinkov atozibana.
Common (may affect less than 1 in 10 people) - Headache. 
Pogosti (neželeni učinki, ki se lahko pojavijo pri manj kot 1 od 10 bolnic) - Glavobol.
- Being sick (vomiting). 
- Slabost (bruhanje).
If you are pregnant and breast-feeding an earlier child, you should stop breast-feeding while you are given Atosiban SUN. 
Nosečnost in dojenje Če ste noseči in dojite starejšega otroka, boste morali prenehati z dojenjem, dokler dobivate zdravilo
- Then another continuous infusion (drip) at a dose of 6 mg per hour will be given for up to 
- Nato boste prejeli še drugo kontinuirano (kapalno) infuzijo v odmerku 6 mg na uro.
Atosiban SUN works by making the contractions in your womb (uterus) weaker. 
Zdravilo Atoziban SUN ublaži maternične kontrakcije (popadke).
54 mg infusion Up to 45 hours subsequent 
Nadaljnja do 45 ur intravenska infuzija
OTHER EU/1/13/852/001 
DRUGI PODATKI EU/1/13/852/001
Atosiban passes the placenta. 
Atoziban prehaja skozi placento.
The intravenous infusion is prepared by diluting Atosiban SUN 37.5 mg/5 ml, concentrate for solution for infusion in sodium chloride 9 mg/ml (0.9%) solution for injection, Ringer's lactate solution or 5% w/v glucose solution. 
Raztopino zdravila za intravensko infuzijo se pripravi tako, da se zdravilo Atobisan SUN 37,5 mg/5 ml koncentrat za raztopino za infundiranje razredči v 9 mg/ml (0,9 %) raztopini natrijevega klorida za injiciranje, raztopini Ringerjevega laktata ali 5 % (w/v) raztopini glukoze.
Atosiban SUN contains atosiban (INN), a synthetic peptide ([Mpa1, D-Tyr(Et)2, Thr4,Orn8]-oxytocin) which is a competitive antagonist of human oxytocin at receptor level. 
Zdravilo Atoziban SUN vsebuje atoziban (INN), sintetičen peptid ([Mpa1, D-Tyr(Et)2, Thr4,Orn8]
OTHER EU/1/13/852/002 
DRUGI PODATKI EU/1/13/852/002
- If you have something called “severe pre-eclampsia” and your doctor wants your unborn baby to be delivered straight away. 
- Če imate hudo preeklampsijo in zdravnik meni, da je treba porod opraviti takoj.
The atosiban 6.75 mg/0.9 ml solution for injection should be used immediately. 
Atoziban 6,75 mg/0,9 ml raztopina za injiciranje morate uporabiti takoj.
How to store Atosiban SUN 
Shranjevanje zdravila Atoziban SUN
What you need to know before you are given Atosiban SUN 
Kaj morate vedeti, preden boste prejeli zdravilo Atoziban SUN Ne smete prejeti zdravila Atoziban SUN
During treatment with Atosiban SUN, your contractions and your unborn baby's heart rate may be monitored. 
Med zdravljenjem z zdravilom Atoziban SUN bodo po potrebi nadzirali kontrakcije vaše maternice in srčno frekvenco ploda.
For storage conditions after first opening and dilution of the medicinal product, see section 6.3. 
Za pogoje shranjevanja po prvem odprtju in redčenju zdravila glejte poglavje 6.3. 6.5 Vrsta ovojnine in vsebina
In atosiban clinical trials no effects were observed on breast-feeding. 
V kliničnih preskušanjih atozibana učinkov na dojenje niso opazili.
Do not use Atosiban SUN if you notice particulate matter and discoloration prior to administration. 
Ne uporabljajte zdravila Atoziban SUN, če opazite trdne delce ali spremembo barve.
Atosiban dose 
po razredčitvi
Reproductive system and breast disorder 
Motnje reprodukcije in dojk maternična krvavitev,
Monitoring of uterine contractions and fetal heart rate during administration of atosiban and in case of persistent uterine contractions should be considered. 
Med uporabo atozibana in v primeru trajnih kontrakcij maternice je treba razmisliti o nadziranju kontrakcij in spremljanju plodovega srčnega utripa.
Atosiban SUN is used to delay the premature birth of your baby. 
Zdravilo Atoziban SUN se uporablja za preprečitev prezgodnjega poroda.
Very common (may affect more than 1 in 10 people) - Feeling sick (nausea). 
Zelo pogosti (neželeni učinki, ki se lahko pojavijo pri več kot 1 od 10 bolnic) - Siljenje na bruhanje (navzea).
If you get any side effects, talk to your doctor, midwife or pharmacist. 
Če opazite katerega koli izmedneželenih učinkov, se posvetujte z zdravnikom, z babico ali farmacevtom.
It does this by blocking the effect of a natural hormone in your body called “oxytocin” which causes your womb (uterus) to contract. 
Zdravilo zavira učinek naravnega hormona oksitocina, ki povzroča krčenje maternice
One vial of solution for injection contains 0.9 ml solution, corresponding to 6.75 mg atosiban. 
Ena viala z raztopino za injiciranje vsebuje 0,9 ml raztopine, kar ustreza 6,75 mg atozibana.
Possible adverse reactions of atosiban were described for the mother during the use of atosiban in clinical trials. 
V kliničnih preskušanjih so bili med uporabo atozibana opisani možni neželeni učinki atozibana pri materi.
- Each vial of Atosiban SUN 6.75 mg/0.9 ml solution for injection contains atosiban acetate equivalent to 6.75 mg of atosiban in 0.9 ml. 
- Ena viala zdravila Atoziban SUN 6,75 mg/0,9 ml raztopina za injiciranje vsebuje atozibanijev acetat, ki ustreza 6,75 mg atozibana v 0,9 ml.
What Atosiban SUN looks like and contents of the pack Atosiban SUN 37.5 mg/5 ml concentrate for solution for infusion is a clear, colourless solution without particles. 
Izgled zdravila Atoziban SUN in vsebina pakiranja Zdravilo Atoziban SUN 37,5 mg/5 ml koncentrat za raztopino za infundiranje je bistra, brezbarvna raztopina brez delcev.
In human pre-term labour, atosiban at the recommended dose antagonises uterine contractions and induces uterine quiescence. 
Pri prezgodnjem porodu pri človeku atoziban v priporočenem odmerjanju zavira kontrakcije maternice in maternico umiri.
MARKETING AUTHORISATION NUMBER(S) EU/1/13/852/001 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/13/852/001
Replace it by 10 ml atosiban 37.5 mg/5 ml concentrate for solution for infusion from two 5 ml vials to obtain a concentration of 75 mg atosiban in 100 ml. 
Nadomestite jo z 10 ml atozibana 37,5 mg/5 ml koncentrat za raztopino za infundiranje, ki jih dobite iz dveh 5 ml vial, tako da bo končna koncentracija 75 mg atozibana v 100 ml.
One vial of concentrate for solution for infusion contains 5 ml solution, corresponding to 37.5 mg atosiban. 
Ena viala s koncentratom za raztopino za infundiranje vsebuje 5 ml raztopine, kar ustreza 37,5 mg atozibana.
MARKETING AUTHORISATION NUMBER(S) EU/1/13/852/002 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/13/852/002